Delving into the Latest Updates on 商丘肿瘤防治研究所 with Synapse

概览

疾病领域	数量

肿瘤	1

排名前五的药物类型	数量

重组多肽	1

排名前五的靶点	数量

TNFRSF21(肿瘤坏死因子受体超家族成员21)	1

关联

1

项与商丘肿瘤防治研究所相关的药物

CN114478693

专利挖掘

靶点

TNFRSF21

作用机制-

在研机构

商丘肿瘤防治研究所

原研机构

商丘肿瘤防治研究所

在研适应症

肿瘤

非在研适应症-

最高研发阶段药物发现

首次获批国家/地区-

首次获批日期-

100 项与商丘肿瘤防治研究所相关的临床结果

登录后查看更多信息

0 项与商丘肿瘤防治研究所相关的专利（医药）

登录后查看更多信息

1,215

项与商丘肿瘤防治研究所相关的文献（医药）

2025-02-01·Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

Organoids in lung cancer brain metastasis: Foundational research, clinical translation, and prospective outlooks

Review

作者: Qu, Jialin ; Xing, Ligang ; Xiang, Dongxi ; Zheng, Mei

Brain metastasis stands as a leading contributor to mortality in lung cancer patients, yet the intricate mechanism underlying this phenomenon remains elusive. This underscores the need for robust preclinical models and effective treatment strategies. Emerging as viable in vitro models that closely replicate actual tumors, three-dimensional culture systems, particularly organoids derived from non-malignant cells or cancer organoids, have emerged as promising avenues. This review delves into the forefronts of fundamental research and clinical applications focused on lung cancer brain metastasis-derived organoids, highlighting current challenges and delineating prospects. These studies offer tremendous potential for clinical application despite being in nascent status.

2025-02-01·The Breast

Survival feature and trend of female breast cancer: A comprehensive review of survival analysis from cancer registration data

Review

作者: Wu, Jing ; Zhang, Yan ; Ye, Zhuo-Jun ; Tang, Dan-Dan ; Xu, Qun ; Xiang, Yong-Bing ; Tan, Jing-Yu ; Liu, Wan-Wan

To better understand global patterns, chronological changes, and international comparisons of female breast cancer survival, we reviewed published data from population-based cancer registries worldwide. Using PubMed, Embase, Web of Science, SEER, and SinoMed, a comprehensive literature search was conducted for female breast cancer survival from the population-based cancer registries through 31 December 2023. Observed, relative, and net survival rates and their corresponding age-standardized survival rates since the 1990s were collected and further stratified by prognostic factors. The prognosis of female breast cancer patients was favorable, with 5-year relative survival rates above 80 % in most regions. The trend in breast cancer survival showed annual increases in most countries but was accompanied by geographical disparities. The highest age-standardized 5-year relative survival rate was identified in the USA (2010-2014) at 90.2 %, while the lowest was in India (2010-2014) at 66.1 %. Overall, North America and Oceania had the best survival, and, for Europe, survival was worst in Eastern Europe. The survival in some Asian countries was disturbing. Younger age groups had a better prognosis than those aged 75 years and over. The lowest survival rates were observed in patients with distant metastatic and triple-negative breast cancer. Worldwide, there has been a steady improvement in female breast cancer survival. However, the survival gap between developed and developing countries has remained wide over the past 30 years. Differences in age, stage at diagnosis, and molecular subtype may explain some of the disparities, providing evidence for targeted management strategies.

2025-01-01·Nature Genetics

Refining breast cancer genetic risk and biology through multi-ancestry fine-mapping analyses of 192 risk regions

Article

作者: Guo, Xingyi ; Hennis, Anselm J M ; Obafunwa, John ; Lee, Eun-Sook ; Nemesure, Barbara ; Zhang, Haoyu ; Chen, Zhishan ; O'Brien, Katie M ; Yamaji, Taiki ; Cai, Qiuyin ; Palmer, Julie R ; Zirpoli, Gary ; Choi, Ji-Yeob ; Pal, Tuya ; Matsuo, Keitaro ; Gu, Jian ; Brewster, Abenaa M ; Park, Sue K ; Olopade, Olufunmilayo I ; Long, Jirong ; Jia, Guochong ; Shu, Xiao-Ou ; Makumbi, Timothy ; Bauer, Joshua A ; John, Esther M ; Zhao, Hongyu ; Ito, Hidemi ; Reid, Sonya ; Sanderson, Maureen ; Ojengbede, Oladosu ; Huo, Dezheng ; Shen, Chen-Yang ; Press, Michael F ; Li, Chao ; Park, Boyoung ; Sandler, Dale P ; Butler, Ebonee N ; Barnard, Mollie E ; Olshan, Andrew F ; Xie, Yuhan ; Li, Bingshan ; Hu, Jennifer J ; Ahearn, Thomas ; Huang, Maosheng ; Yao, Song ; Chen, Yu ; Falusi, Adeyinka ; Kang, Daehee ; Cote, Michelle L ; Park, Min-Ho ; Gao, Yu-Tang ; Iwasaki, Motoki ; Matsuda, Koichi ; Zheng, Ying ; Kubo, Michiaki ; Kweon, Sun-Seog ; Ndom, Paul ; Ambs, Stefan ; Li, Christopher I ; Low, Siew-Kee ; Zheng, Wei ; Troester, Melissa A ; Ping, Jie ; Weinberg, Clarice R ; Ambrosone, Christine B ; Nathanson, Katherine L ; Haiman, Christopher A ; Tao, Ran ; Garcia-Closas, Montserrat ; Noh, Dong-Young

Genome-wide association studies have identified approximately 200 genetic risk loci for breast cancer, but the causal variants and target genes are mostly unknown. We sought to fine-map all known breast cancer risk loci using genome-wide association study data from 172,737 female breast cancer cases and 242,009 controls of African, Asian and European ancestry. We identified 332 independent association signals for breast cancer risk, including 131 signals not reported previously, and for 50 of them, we narrowed the credible causal variants down to a single variant. Analyses integrating functional genomics data identified 195 putative susceptibility genes, enriched in PI3K/AKT, TNF/NF-κB, p53 and Wnt/β-catenin pathways. Single-cell RNA sequencing or in vitro experiment data provided additional functional evidence for 105 genes. Our study uncovered large numbers of association signals and candidate susceptibility genes for breast cancer, uncovered breast cancer genetics and biology, and supported the value of including multi-ancestry data in fine-mapping analyses.

100 项与商丘肿瘤防治研究所相关的药物交易

登录后查看更多信息

100 项与商丘肿瘤防治研究所相关的转化医学

登录后查看更多信息